Nav: Home

'Hijacked' cell response to stress reveals promising drug targets for blood cancer

July 23, 2018

A signaling pathway that helps promote normal cell growth worsens a form of leukemia by taking control of another pathway better known for protecting cells from biological stress, a new study shows.

The discovery that the NOTCH1 pathway takes control of heat shock transcription factor 1 (HSF1) signaling in T cell acute lymphoblastic leukemia, or T-ALL, suggests that blocking one or more genes in the HSF1 pathway could represent a new approach in treating the aggressive disease, researchers say.

Moreover, the NYU School of Medicine scientists who led the latest research efforts say that because an experimental anticancer drug is already in development against one of these targets, heat shock protein 90 (HSP90), the new study identifies the subset of T-ALL patients most likely to benefit from the new therapy.

Reporting in the journal Nature Medicine online July 23, researchers say their study is the first to directly link activation of HSF1, which is critical to the production of dozens of other proteins, including HSP90, to any leukemia.

"Our study shows how the NOTCH1 pathway hijacks the heat shock transcription factor 1 pathway to promote tumor growth," says study senior investigator Iannis Aifantis, PhD, professor and chair of the Department of Pathology at NYU Langone Health and its Perlmutter Cancer Center. "The cancer cells are sending into overdrive a system that helps healthy cells respond to stress."

A drug blocking HSP90 is already in early clinical trials elsewhere, led by study co-investigator Gabriela Chiosis, PhD, as a treatment for breast cancer. Aifantis says if further testing proves successful, the experimental drug, labeled PU-H71, could be quickly adapted for trials in T-ALL patients.

And because early experiments with the drug in animals and human cells show that blocking HSP90 kills only cancer cells, Aifantis says its use is likely to have fewer side effects than current T-ALL treatments, such as chemotherapy, which kills both normal and cancer cells.

"Having a targeted therapy that kills only cancer cells could really boost our efforts to treat T cell acute lymphoblastic leukemia, which affects mostly children," says study first author Nikos Kourtis, PhD, a postdoctoral fellow at NYU Langone. Kourtis says currently one in five children treated for the disease relapses within a decade. Attempts at blocking NOTCH1 directly have failed, he notes, because of adverse effects on healthy cells connected to the pathway.

As part of the study, researchers genetically blocked HSF1 in mice induced (through increased NOTCH1 activity) to develop T-ALL, killing all cancer cells but not the mice. This evidence, researchers say, showed that HSF1 was essential to the survival of T-ALL cancer cells. The study also found that no adverse effects resulted and healthy blood cell production was not interrupted when HSF1 was removed from mouse bone marrow stem cells.

Further laboratory experiments in T-ALL mice and human cells showed that silencing the gene behind production of HSP90 efficiently killed leukemia cells, especially those with the highest NOTCH1 and HSP90 activity.

Aifantis says his team next plans to evaluate the effects of another eight proteins produced by genes active in the HSF1 pathway to see if any show promising anticancer activity in T-ALL. The team also hopes to launch clinical trials using HSP90 inhibitors against T-ALL.
-end-
Funding support for the study was provided by National Cancer Institute grants P30 CA016087, R01 CA133379, R01 CA105129, R01 CA149655, R01 CA173636, and R01 CA194923; American Cancer Society grant RSG-15-189-01; and Leukemia & Lymphoma Society new idea award 8007-17.

Besides Aifantis and Kourtis, other NYU Langone researchers involved in the study were Charalampos Lazaris, PhD; Kathryn Hockemeyer, MD, PhD; Jasper Mullenders, PhD; Yixiao Gong; Thomas Trimarchi, PhD; Kamala Bhatt; Hai Hu; and Aristotelis Tsirigos, PhD.

Additional research support was provided by Juan Carlos Balandran, Alejandra Jimenez, and Monica Guzman at Weill Cornell Medical College; Liza Shrestha and Chiosis at Memorial Sloan Kettering Cancer Center; Alberto Ambesi-Impiombato and Adolfo Ferrando, at Columbia University; and Elisabeth Paietta at Montefiore Medical Center -- all in New York. Another study co-investigator is Michelle Kelliher at the University of Massachusetts Medical School in Worcester.

Media Inquiries:

David March
12-404-3528
david.march@nyumc.org

NYU Langone Health / NYU School of Medicine

Related Cancer Cells Articles:

Cancer cells send signals boosting survival and drug resistance in other cancer cells
Researchers at University of California San Diego School of Medicine report that cancer cells appear to communicate to other cancer cells, activating an internal mechanism that boosts resistance to common chemotherapies and promotes tumor survival.
A protein that stem cells require could be a target in killing breast cancer cells
Researchers have identified a protein that must be present in order for mammary stem cells to perform their normal functions.
Single gene encourages growth of intestinal stem cells, supporting 'niche' cells -- and cancer
A gene previously identified as critical for tumor growth in many human cancers also maintains intestinal stem cells and encourages the growth of cells that support them, according to results of a study led by Johns Hopkins researchers.
Prostate cancer cells grow with malfunction of cholesterol control in cells
Advanced prostate cancer and high blood cholesterol have long been known to be connected, but it has been a chicken-or-egg problem.
Immune therapy scientists discover distinct cells that block cancer-fighting immune cells
Princess Margaret Cancer Centre scientists have discovered a distinct cell population in tumours that inhibits the body's immune response to fight cancer.
New system developed that can switch on immune cells to attack cancer cells
Researchers have developed an artificial structure that mimics the cell membrane, which can switch on immune cells to attack and destroy a designated target.
Hybrid immune cells in early-stage lung cancer spur anti-tumor T cells to action
Researchers have identified a unique subset of these cells that exhibit hybrid characteristics of two immune cell types -- neutrophils and antigen-presenting cells -- in samples from early-stage human lung cancers.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Sleep hormone helps breast cancer drug kill more cancer cells
Tiny bubbles filled with the sleep hormone melatonin can make breast cancer treatment more effective, which means people need a lower dose, giving them less severe side effects.
Breast cancer tumor-initiating cells use mTOR signaling to recruit suppressor cells to promote tumor
Baylor College of Medicine researchers report a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.

Related Cancer Cells Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Changing The World
What does it take to change the world for the better? This hour, TED speakers explore ideas on activism—what motivates it, why it matters, and how each of us can make a difference. Guests include civil rights activist Ruby Sales, labor leader and civil rights activist Dolores Huerta, author Jeremy Heimans, "craftivist" Sarah Corbett, and designer and futurist Angela Oguntala.
Now Playing: Science for the People

#521 The Curious Life of Krill
Krill may be one of the most abundant forms of life on our planet... but it turns out we don't know that much about them. For a create that underpins a massive ocean ecosystem and lives in our oceans in massive numbers, they're surprisingly difficult to study. We sit down and shine some light on these underappreciated crustaceans with Stephen Nicol, Adjunct Professor at the University of Tasmania, Scientific Advisor to the Association of Responsible Krill Harvesting Companies, and author of the book "The Curious Life of Krill: A Conservation Story from the Bottom of the World".